Key Details
Price
$1.61Annual ROE
-30.56%Beta
1.03Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.
The heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, Massachusetts. The poster will contain updated clinical data from the study as of September 5, 2023.
The average of price targets set by Wall Street analysts indicates a potential upside of 182.6% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference taking place in Dana Point, California June 12-15, 2023. The company will also be available to meet one-on-one with institutional investors at the conference. Details on the fireside chat can be found below.
FAQ
- What is the primary business of PMV Pharmaceuticals?
- What is the ticker symbol for PMV Pharmaceuticals?
- Does PMV Pharmaceuticals pay dividends?
- What sector is PMV Pharmaceuticals in?
- What industry is PMV Pharmaceuticals in?
- What country is PMV Pharmaceuticals based in?
- When did PMV Pharmaceuticals go public?
- Is PMV Pharmaceuticals in the S&P 500?
- Is PMV Pharmaceuticals in the NASDAQ 100?
- Is PMV Pharmaceuticals in the Dow Jones?
- When was PMV Pharmaceuticals's last earnings report?
- When does PMV Pharmaceuticals report earnings?
- Should I buy PMV Pharmaceuticals stock now?